Navigation Links
AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
Date:3/6/2009

SAN DIEGO, March 6 /PRNewswire/ -- AndroScience Corporation (ASC(TM)), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9(TM) cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.

ASC-J9(TM) demonstrated a clinical benefit in reducing inflammatory lesions compared to placebo at certain dosages and at multiple time points during the study, though the study was not powered for statistical significance. ASC will now focus on bolstering efficacy through a new formulation and intends on forming a co-development or licensing partnership for future clinical development and commercialization. Through enhancing androgen receptor protein degradation, ASC-J9(TM) represents the first topical agent directed at modulating the effect of androgens (male hormones), through the androgen receptor, a key causative factor in the pathogenesis of acne.

Charles Shih, Ph.D., Chief Executive Officer of AndroScience Corporation, said, "We are extremely enthusiastic about the therapeutic potential of ASC-J9(TM) and the remarkable safety profile exhibited by the drug. The 0.025% cream formulation dose of ASC-J9(TM) delivered a therapeutic benefit comparable to levels seen with marketed acne drugs on inflammatory lesions, with no side effects, and we believe a higher dosage or improved formulation will translate to even greater efficacy in the treatment of acne."

ASC-J9(TM) is a small molecule with a novel mechanism of action, which selectively enhances androgen receptor degradation (ARD) to reduce androgen activity. ARD enhancers act on a key cause of acne, the androgen activation system, through reducing high levels of androgen receptor present in the sebaceous gland to lower sebum secretion, a fundamentally different approach from all other current acne treatments. ASC-J9(TM) cream is topically administered and exhibits low systemic absorption, limiting systemic side effect risks and allowing for the treatment of both males and females.

In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based approaches.

AndroScience Corporation

www.androscience.com


'/>"/>
SOURCE AndroScience Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets
4. Christie Cookie Recalls Certain Lots of Peanut Butter Cookie Dough Due to Expanded Recall by Peanut Corporation of America
5. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
6. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
7. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
10. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
11. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical ... MBA as Chief Medical Officer. Dr Weinberg will be based in ... ... more than 17 years as a pharmaceutical and biotech executive with ... the course of his career, he has interfaced with the US ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
(Date:1/19/2017)... 19, 2017 This report on the opioid ... scenario of the global market. Large number of chronic ... chronic constipation is a major side effect of consumption ... novel targeted therapy has been prescribed to treat opioid ... targeted medicines, and growing awareness about the therapy are ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... , ... Source Vitál Apothecary, a skin and body care company dedicated to ... had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference ... the nutritional, sports and health industries a chance to meet in private sessions with ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice ... in families with school-aged children since the holiday season. , “It happens every ... their families, sharing hugs and taking photos, which is the head-to-head gateway that lice ...
(Date:1/20/2017)... boca raton florida (PRWEB) , ... January 20, 2017 , ... ... trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has ... and her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how ... You” is the creation of published author, Stephen Miller, who, for over ten long years ... given to him. Born in Trinidad and Tobago, he has been serving the Lord for ...
Breaking Medicine News(10 mins):